Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

NCT04853043 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
7
Enrollment
OTHER
Sponsor class

Stopped PI Determination - Slow recruitment, funding concerns, poor response to treatment

Conditions

Interventions

Sponsor

University of Utah

Collaborators